A pivotal dose ranging, randomized, placebo-controlled phase 2b/3 clinical trial of ABX464 in the patients with Crohn's Disease
Latest Information Update: 02 Jun 2021
Price :
$35 *
At a glance
- Drugs Obefazimod (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors Abivax
- 24 May 2021 According to an Abivax media release, this study is expected to be initiated before year end.
- 24 Sep 2020 According to an Abivax media release, this study is expected to start patient recruitment beginning of 2021.
- 16 Mar 2020 According to an Abivax media release, the company plans to start enrollment in second half of 2020.